GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » 14-Day RSI

Recordati SpA (Recordati SpA) 14-Day RSI : 93.59 (As of May. 02, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-02), Recordati SpA's 14-Day RSI is 93.59.

The industry rank for Recordati SpA's 14-Day RSI or its related term are showing as below:

RCDTF's 14-Day RSI is ranked better than
57.52% of 1144 companies
in the Drug Manufacturers industry
Industry Median: 51.07 vs RCDTF: 93.59

Competitive Comparison of Recordati SpA's 14-Day RSI

For the Drug Manufacturers - General subindustry, Recordati SpA's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Recordati SpA's 14-Day RSI falls into.



Recordati SpA  (OTCPK:RCDTF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA  (OTCPK:RCDTF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Recordati SpA 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Recordati SpA's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020